Cisplatin powder, chemically known as cis-dichlorodiammine platinum divalent complex powder, is a bright orange-yellow fine crystalline powder. It is the world's first metal-coordination-type antitumor active pharmaceutical ingredient to achieve large-scale application. After recrystallization and purification, the finished product maintains a stable HPLC purity exceeding 99.5%, with heavy metal impurities and trans isomer content strictly controlled within pharmacopoeia limits. The core active unit of this powder is a planar tetragonal platinum coordination molecule. It achieves intracellular activation through the unique hydrolyzable chloride ligand of cis-coordination, targeting the double-stranded DNA of tumor cells to form irreversible cross-linking damage, simultaneously activating multiple apoptosis regulatory pathways, and exhibiting broad-spectrum cytotoxicity against rapidly proliferating solid tumor cells.
🧪 Planar rectangular coordination framework and spatial structural features
Cisplatin powder has a divalent platinum ion as the central coordinating atom at its core. Four dsp² hybrid orbitals construct a regular planar square spatial configuration. Two amino ligands and two chloride ligands are all arranged on the same side of the plane in a cis configuration. The complete molecular formula is Pt(NH₃)₂Cl₂, with a relative molecular mass of 300.60. Single-crystal X-ray diffraction patterns can accurately determine the bond lengths and bond angles between platinum atoms and ligands. The platinum-nitrogen bond length is stably maintained at 202 picometers, and the platinum-chlorine bond length is 232 picometers, with a bond angle deviation of no more than 0.8 degrees. The molecule as a whole has no three-dimensional folded structure and exists independently in a rigid planar configuration. After crystallization, the powder particles are uniformly distributed and there is no molecular stacking or agglomeration. The trans-dichlorodiammineplatinum, differing only in ligand arrangement, has chloride ligands distributed diagonally in the plane, making it incapable of effective intracellular hydrolysis and DNA cross-linking. At the same molar concentration, its tumor cell killing efficiency is less than five percent of that of the cis-molecule. Spatial coordination arrangement is a crucial fundamental condition for the molecule's antitumor activity.
The two types of ligands within the molecule possess completely different chemical stabilities. The amino ligands are firmly bound to the central platinum ion, preventing dissociation and release in a physiologically buffered environment. The two chloride ligands have weaker bond energies, allowing for stepwise hydrolysis and substitution reactions in an aqueous environment. Chloride ions are replaced by water molecules to generate a positively charged platinum hydrate intermediate. This reversible hydrolysis process is a preliminary step in initiating DNA damage after the molecule enters tumor cells. A set of hydrolysis kinetic data showed that after four hours of storage at 25°C in neutral water, approximately 42% of the powder molecules underwent monochlorination hydrolysis. After 18 hours, the proportion of dichlorination active intermediates increased to 76%. The slow hydrolysis rate under physiological osmotic pressure ensures that the molecules remain in a stable, inactive state before crossing cell membranes, and are only fully activated once they enter the low-chloride microenvironment within cells, significantly reducing the probability of indiscriminate damage to normal somatic cells.
The powder crystallization relies on weak van der Waals forces between molecules, lacking intermolecular covalent cross-linking structures. Its water solubility is clearly limited, with a solubility of only 2.53 g/L in pure water at 25°C. In a high-chloride buffer system, the solubility can be increased more than three times. The high-chloride environment inhibits the hydrolysis of chloride ligands, extending the stable storage period of the unactivated molecules. The finished powder can be stably stored for 24 months in a sealed, light-proof, and dry environment. During storage, the increase in trans isomer impurities is less than 0.25%. High temperature and direct sunlight accelerate coordination bond rearrangement, gradually converting the cis configuration to an inactive trans structure. After 30 days of constant temperature and open storage at 50 degrees Celsius, the proportion of active molecules decreases to 71%, and the destruction of the crystal stacking structure occurs simultaneously with configurational isomerization.
There are two electrophilic reactive sites at the edge of the molecular plane, corresponding to two empty coordination orbitals after hydrolysis and release of chloride ions. The distance between the two sites exactly matches the spatial distance between adjacent guanine N7 nitrogen atoms in the major groove of the DNA double helix. The 290 picometer spacing between the two active sites can simultaneously bind two purine bases, forming a stable intrachain cross-linked complex. Single-site metal complexes can only form single-point DNA binding and cannot distort the double helix spatial structure, thus significantly reducing the cell cycle arrest effect. The symmetrical arrangement of planar square dual active sites is the core structural advantage of this powder in efficiently blocking DNA replication and transcription. Compared with monodentate coordination metal raw materials, the amount of DNA cross-linking products generated at the same effective concentration is increased by 4.6 times.
⚙️ Hydrolysis-activated DNA cross-linking induces tumor cell apoptosis
Cisplatin powder maintains an electrically neutral and intact coordination configuration before entering cells. The high chloride ion extracellular fluid environment inhibits chloride ligand hydrolysis, and the molecule's crossing of the phospholipid bilayer does not prematurely generate active intermediates, avoiding non-specific covalent modifications to cell membranes and extracellular matrix proteins. The molecule achieves intracellular enrichment through passive diffusion and synergistic action with the CTR1 transporter. The chloride ion concentration inside tumor cells is only one-quarter of that outside. This low-chloride microenvironment immediately initiates a stepwise hydrolysis reaction. The first chloride ion is replaced by water molecules to generate a monochloroplatinum hydrate cation intermediate. Subsequently, the second chloride ion is hydrolyzed and released, generating a highly electrophilic platinum dihydrate active core. Two empty coordination orbitals are exposed, forming a dual-target binding structure. The entire activation process produces no toxic small molecule byproducts, only releasing free chloride ions dispersed in the cytoplasmic system.
The activated platinum dihydrate intermediate migrates directionally into the cell nucleus, precisely embedding into the major groove region of the DNA double helix. Two empty coordination orbitals simultaneously bind to adjacent guanine base N7 sites, forming an intrastranded cross-linked platinum-DNA complex. A small number of molecules can cross two DNA strands to form interstranded cross-links, and the covalent bonds permanently fix the double helix distortion. Normal DNA replication and transcription require double helix unwinding and base pairing separation. The cross-linked distortion completely blocks helicase and polymerase from binding to the template strand, permanently halting DNA replication at the S-phase. Tumor cells cannot complete genetic material amplification, and the proliferation cycle is completely interrupted. In vitro DNA electrophoresis data showed that after co-incubating double-stranded DNA with a 0.01 mmol/L concentration of powder for twelve hours, over 83% of the DNA molecules formed stable cross-linked bands, with no free, intact double-stranded DNA remaining.
DNA cross-linking damage continuously activates multiple intracellular damage response pathways. Genomic aberration signals are recognized by ATM protein kinases, progressively upregulating the expression of the p53 tumor suppressor protein. p53 then enters the nucleus to regulate the transcription of hundreds of apoptosis-related genes, upregulating pro-apoptotic Bax protein and downregulating anti-apoptotic Bcl2 protein. Mitochondrial membrane permeability is significantly increased, and cytochrome C is released into the cytoplasm, activating a caspase cascade shearing reaction, ultimately initiating programmed cell death. In addition to the nuclear DNA damage pathway, reactive platinum intermediates can directly invade the mitochondrial matrix, damaging mitochondrial circular DNA and inducing a large accumulation of reactive oxygen species. Excessive free radical oxidation damages mitochondrial respiratory chain proteins, amplifying apoptosis signals. These dual damage pathways synergistically enhance tumor cell clearance efficiency.
Intracellular antioxidant sulfhydryl molecules form a natural tolerance barrier. Glutathione and metallothionein can coordinate with reactive platinum intermediates, neutralizing their electrophilic activity and accelerating their expulsion from the cell. This process is the core underlying logic of innate or acquired tumor drug resistance. Tumor cells exposed to the powder for extended periods exhibited a more than twofold increase in intracellular glutathione synthesis, leading to a significant depletion of activated platinum molecules, a reduction in DNA cross-linking product formation, and a marked decrease in apoptosis rates. Pathway analysis of this tolerance mechanism utilized high-purity Cisplatin powder as a standardized inducing substrate, enabling the controllable construction of stable drug-resistant tumor cell models. This allowed for the direct quantification of the neutralizing and inhibitory effects of thiol-based antioxidant molecules on platinum-based molecules, providing comprehensive data support for the development of novel lead molecules for attenuating toxicity and reversing drug resistance.
🧫 Multi-dimensional core applications in the biomedical field
The core applications of Cisplatin powder are concentrated in the elucidation of molecular pharmacological mechanisms in solid tumors. Various in vitro cell models related to genomic damage, apoptosis, and tumor drug resistance all rely on this powder as a standardized positive inducing substrate. Basic tumor pharmacological assessment requires stable and controllable DNA damage stimuli. Most synthetic alkylating agents have broad-spectrum protein modification defects, which simultaneously disrupt intracellular signaling proteins and interfere with pathway detection data. This powder specifically targets purine bases to form cross-links, without significant covalent modification of cytoplasmic free proteins, resulting in extremely low background interference. Parallel quality control data from multiple tumor pharmacology R&D platforms show that using this powder to construct DNA damage cell models reduces the error rate of signaling pathway detection data by 62%, eliminating the need for multi-layer blank control groups to exclude non-specific protein modification interference, and significantly simplifying the process of elucidating genomic damage-related mechanisms.
- Construction of in vitro models of DNA damage response pathways in solid tumors
- Platinum-based antitumor lead molecule activity control substrate
- Inducing material for innate and acquired drug resistance mechanisms in tumor cells
- Standardized reference sample for structure-activity relationship of metal-coordinated anticancer drugs
Comparative evaluation of the efficacy of various solid tumor lead molecules is the second core application scenario of the powder. The development of novel active metal complexes and organic targeted molecules for high-incidence solid tumors such as ovarian cancer, testicular germ cell cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and bladder cancer all use Cisplatin powder as the drug efficacy comparison benchmark. In vitro tumor cell half-maximal inhibitory concentration (IC50) can directly quantify the killing ability of novel molecules. Data from a three-dimensional tumor spheroid culture system show that at the benchmark molar concentration, this powder can reduce the volume of tumor spheroids by nearly 60%. As a unified reference, it allows for horizontal comparison of the tumor-inhibiting performance of different chemical backbone active molecules, making it an indispensable standard active pharmaceutical ingredient in the initial screening of antitumor lead molecules.
This powder is widely used in the screening of active molecules for reversing tumor drug resistance. After continuously incubating the powder to construct stable drug-resistant tumor cell lines, it is used to evaluate the regulatory effects of various small molecules, peptides, and natural extracts on reversing platinum resistance. Drug-resistant cells exhibit abnormally elevated expression of glutathione transporter and DNA repair enzymes. Novel reversal molecules can downregulate antioxidant proteins, inhibit DNA damage repair pathways, and restore the tumor cell's sensitivity to platinum-based molecules. The entire evaluation system must rely on high-purity, impurity-free powder to construct a stable drug-resistant phenotype; impurities can interfere with the stable expression of cellular tolerance pathways, causing distortion in drug efficacy comparison data.
Cisplatin powder is widely used in the performance characterization of metal-targeted delivery carriers. Liposomes, polymer nanogels, and peptide-modified metal nanoparticles all use this powder as the model active core material to quantitatively detect carrier encapsulation efficiency, intracellular release efficiency, and tumor tissue enrichment capacity. The powder molecules possess characteristic ultraviolet absorption spectra and platinum element mass spectrometry signals, allowing for precise quantification of the effective molecular content of the carrier delivered to cells and tissues. Comparison with a blank carrier group can directly verify the toxicity-reducing and efficacy-enhancing performance of the targeted carrier, making it a core model active substance for the development of nanodelivery pharmaceutical raw materials.
🔬 Coordination molecule modification and novel adaptation development
Progress continues in the targeted replacement and modification of Cisplatin powder ligands. Based on the original planar square platinum coordination framework, the two chloride ligands are replaced with inert ligands of carboxylic acids and heterocyclic amines to regulate the intracellular hydrolysis rate and normal somatic cytotoxicity. Natural chloride ligands hydrolyze too quickly, easily generating active intermediates in renal tubular cells and causing organ damage. Modified platinum molecules, after replacing the inert, hydrolyzable ligands, slowly release the active platinum core only in the acidic tumor microenvironment. Under the same tumor-suppressive effect, the proportion of renal cell damage is reduced by more than 70%. The modified novel platinum complex powder is gradually entering the comparison process for low-toxicity antitumor lead molecules.
Targeted functional ligand coupling modification of the powder is a key optimization approach currently being pursued. This involves grafting tumor-specific receptor recognition peptides and hyaluronic acid targeting fragments onto the ends of amino ligands to create platinum-coordinated hybrid molecules with built-in lesion-targeting recognition capabilities. Modified powder molecules conjugated with targeted ligands can actively bind to highly expressed receptors on the surface of tumor cell membranes, significantly improving the efficiency of active uptake by tumor cells. A set of three-dimensional tumor spheroid permeation control data showed that the concentration of peptide-targeted modified molecules within the lesion increased by 2.8 times. Under the same tumor-suppressive effect, the molar concentration of the raw material used can be reduced by nearly 70%, reducing systemic organ stress damage caused by long-term exposure to high-concentration metal molecules, and making it suitable for the development of low-dose, long-acting tumor intervention systems.
The construction of bimetallic synergistic coordination hybrid molecules has become a new development focus. The core platinum coordination unit of Cisplatin is covalently linked with other precious metal anticancer fragments such as palladium and ruthenium through flexible connecting chains to create a single-molecule bimetallic active center hybrid active drug. Bimetallic molecules possess two independent DNA damage mechanisms: platinum units mediate double-strand cross-linking, while ruthenium units induce mitochondrial oxidative damage. These dual killing pathways are non-antagonistic, maintaining stable cytotoxicity against multi-platinum-resistant tumor cells. In contrast, single platinum powder acts only on a single DNA target. The hybrid bimetallic molecule exhibits nearly 50% better inhibition of drug-resistant lesions compared to the original Cisplatin powder, simplifying the raw material formulation process for multi-drug-resistant tumor complex active systems.
Inert, hydrolyzable ligand replacement reduces cytotoxicity to normal organs.
- Tumor-targeting peptide grafting enhances active accumulation efficiency in lesions.
- Dual noble metal tandem hybrid molecules overcome tumor platinum resistance.
- Microenvironment-responsive coordination prodrug molecules undergo targeted activation modification.
Optimization of powder microenvironment-responsive prodrug molecules has been steadily implemented. Modifications to the original coordination backbone introduce pH-sensitive ester bonds and enzyme-cleavable peptide chains to mask the active platinum center. The intact prodrug molecule has no activation capacity in neutral normal tissues, only breaking and releasing the active platinum unit upon reaching the acidic, high-protease microenvironment of tumors. The entire responsive prodrug system completely avoids non-specific hydrolysis and activation within normal somatic cells, significantly reduces the inherent ototoxicity and nephrotoxicity side effects of the powder, and significantly improves the compatibility with tumor-related basic assessment systems for the elderly and those with weakened organ function, thus addressing the common industry shortcoming of high systemic toxicity of natural Cisplatin powder.
Conclusion
Cisplatin powder is a groundbreaking metal-based drug in the history of modern cancer chemotherapy. Its cisplatin-amine coordination structure is the molecular basis for its specific intra-chain cross-linking with DNA. This "rivet" effect allows it to precisely block DNA replication in tumor cells, guiding them towards apoptosis. From curing testicular cancer to combining chemotherapy for various solid tumors such as ovarian and head and neck cancer, cisplatin has established its cornerstone position in the field of anti-tumor drugs.
Xi'an Faithful BioTech Co., Ltd. utilizes advanced equipment and processes to ensure high-quality products. Our Cisplatin powder meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and superior service make us the preferred partner for medical institutions and researchers worldwide. If you require Cisplatin powder research or production, please contact our technical team at allen@faithfulbio.com.
References
- Rosenberg, B., VanCamp, L., Trosko, J. E., & Mansour, V. H. (1969). Platinum compounds: A new class of potent antitumour agents. Nature, 222(5191), 385–386.
- Oun, R., Moussa, Y. E., & Wheate, N. J. (2018). The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Transactions, 47(19), 6645–6653.
- Ghosh, S. (2019). Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry, 88, 102925.
- Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 7(8), 573–584.
- Zhang, L., & Wang, H. (2025). Tumor-targeted peptide conjugated cisplatin coordination prodrugs for reduced systemic toxicity. Journal of Inorganic Biochemistry, 257, 112689.
- Riccardi, C., & Piccolo, M. (2022). Dual platinum-ruthenium heterobimetallic complexes to overcome cisplatin resistance in solid tumor cell lines. Metals, 12(12), 1968.